Expression of CD133 and CD24 and their different phenotypes in urinary bladder carcinoma

References

• Kashyap V, Rezende NC, Scotland KB, et al. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev. 2009;18(7):1093–1108. doi:10.1089/scd.2009.011319480567
   PubMed Web of Science ®Google Scholar
• Marcinkiewicz K, Scotland KB, Boorjian SA, et al. The androgen receptor and stem cell pathways in prostate and bladder cancers (review). Int J Oncol. 2012;40(1):5–12. doi:10.3892/ijo.2011.121221956088
   PubMed Web of Science ®Google Scholar
• Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. Rev Br J Cancer. 2010;103(4):439–445. doi:10.1038/sj.bjc.6605821
   PubMed Web of Science ®Google Scholar
• Bentivegna A, Conconi D, Panzeri E, et al. Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. Cancer Sci. 2010;101(2):416–424. doi:10.1111/j.1349-7006.2009.01414.x19961489
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV, Target for cancer therapy: proliferating cells or stem cells. Leukemia. 2006;20(3):385–391. doi:10.1038/sj.leu.240407516357832
   PubMed Web of Science ®Google Scholar
• Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clin Transl Med. 2018;7(1):18. doi:10.1186/s40169-018-0198-129984391
   PubMedGoogle Scholar
• Lee JH, Kim SH, Lee ES, Kim YS. CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep. 2009;22(5):1149–1156.19787233
   PubMed Web of Science ®Google Scholar
• Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol. 2012;2012:708036. doi:10.1155/2012/70803622693526
   PubMedGoogle Scholar
• Choi D, Lee HW, Hur KY, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol. 2009;15(18):2258–2264.19437567
   PubMed Web of Science ®Google Scholar
• Choi YL, Lee SH, Kwon GY, et al. Overexpression of CD24: association with invasiveness in urothelial carcinoma of the bladder. Arch Pathol Lab Med. 2007;131(2):275–281. doi:10.1043/1543-2165(2007)131[275:OOCAWI]2.0.CO;217284113
   PubMed Web of Science ®Google Scholar
• Meacham CE, Morrison SJ. Tumor heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328–337. doi:10.1038/nature1262424048065
   PubMed Web of Science ®Google Scholar
• Liu HG, Zhang XH. How to estimate cancer stem cell frequency correctly. Asian Pac J Cancer Prev. 2009;10(4):711–714.19827901
   PubMedGoogle Scholar
• Ortiz-Montero P, Liu-Bordes WY, Londoño-Vallejo A, Vernot JP. CD24 expression and stem-associated features define tumor cell heterogeneity and tumorigenic capacities in a model of carcinogenesis. Cancer Manag Res. 2018;10:5767–5784. doi:10.2147/CMAR.S17665430510447
   PubMed Web of Science ®Google Scholar
• Shi C, Tian R, Wang M, et al. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther. 2010;10(11):1182–1190.20948317
   PubMed Web of Science ®Google Scholar
• He Y, Xue C, Yu Y, et al. CD44 is overexpressed and correlated with tumor progression in gallbladder cancer. Cancer Manag Res. 2018;10:3857–3865. doi:10.2147/CMAR.S17568130288117
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Moch H, Ulbright TM, Reuter VE. The 2016 WHO classification of tumors of the urinary system and male genital organs- part b.Prostate and bladder tumors. Eur Urol. 2016;70(1):106–119. doi:10.1016/j.eururo.2016.02.02826996659
   PubMed Web of Science ®Google Scholar
• Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8 ed. Cham, Switzerland: Springer; 2017.
   Google Scholar
• Saigusa S, Tanaka K, Toiyama Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009;16(12):3488–3498. doi:10.1245/s10434-009-0617-z19657699
   PubMed Web of Science ®Google Scholar
• Edaghat S, Gheytanchi E, Asgari M, Roudi R, Keymoosi H, Madjd Z. Expression of cancer stem cell markers OCT4 and CD133 in transitional cell carcinomas. Appl Immunohistochem Mol Morphol. 2017;25(3):196–202. doi:10.1097/PAI.000000000000029126945449
   PubMedGoogle Scholar
• Bake M. Cancer stem cells, becoming common. Nat Rep Stem Cells. 2008. doi:10.1038/stemcells.2008.153
   Google Scholar
• Heuser M, Sly LM, Argiropolous B, et al. Modeling the functional heterogeneity of leukaemia stem cells: role of STAT5 in leukaemia stem cell self-renewal. Blood. 2009;114(19):3983–3993. doi:10.1182/blood-2009-04-21552519667399
   PubMed Web of Science ®Google Scholar
• Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumor progression. Rev J Biomed Sci. 2018;25(1):20. doi:10.1186/s12929-018-0426-4
   PubMedGoogle Scholar
• Sell S. On the stem cell origin of cancer. Am J Pathol. 2010;176(6):2584–2594. doi:10.2353/ajpath.2010.09106420431026
   PubMed Web of Science ®Google Scholar
• Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. Rev J Cell Biol. 2012;198(3):281–293. doi:10.1083/jcb.201202014
   PubMed Web of Science ®Google Scholar
• Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67(9):4010–4015. doi:10.1158/0008-5472.CAN-06-418017483311
   PubMed Web of Science ®Google Scholar
• Huang P, Watanabe M, Kaku H, et al. Cancer stem cell-like characteristics of a CD133(+) subpopulation in the J82 human bladder cancer cell line. Mol Clin Oncol. 2013;1(1):180–184. doi:10.3892/mco.2012.2924649144
   PubMedGoogle Scholar
• Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000;163(1):60–62. doi:10.1016/S0022-5347(05)67972-410604314
   PubMed Web of Science ®Google Scholar
• Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor‐initiating cells. PNAS. 2009;106(33):14016–14021. doi:10.1073/pnas.090654910619666525
   PubMed Web of Science ®Google Scholar
• Piccirillo SGM, Combi R, Cajola L, et al. Distinct pools of cancer stem‐like cells coexist within human glioblastomas and display different tumorigenicity and indipendent genomic evolution. Oncogene. 2009;28(15):1807–1811. doi:10.1038/onc.2009.2719287454
   PubMed Web of Science ®Google Scholar
• Botchkina IL, Rowehl RA, Rivadeneira DE, et al. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Cancer Genomics Proteomics. 2009;6(1):19–29.19451087
   PubMedGoogle Scholar
• Günther HS, Schmidt NO, Phillips HS, et al. Glioblastoma‐derived stem cell‐enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008;27(20):2897–2909. doi:10.1038/sj.onc.121094918037961
   PubMed Web of Science ®Google Scholar
• Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Rev Nat Med. 2009;15(9):1010–1012. doi:10.1038/nm0909-1010
   PubMed Web of Science ®Google Scholar
• Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138(5):822–829. doi:10.1016/j.cell.2009.07.04219737509
   PubMed Web of Science ®Google Scholar
• Al‐Hajj M, Wicha MS, Benito‐Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983–3988. doi:10.1073/pnas.053029110012629218
   PubMed Web of Science ®Google Scholar
• Wu Y, Wu P. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18(8):1127–1134. doi:10.1089/scd.2008.033819409053
   PubMed Web of Science ®Google Scholar
• Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69–82. doi:10.1016/j.ccr.2006.11.02017222791
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66(16):7843–7848. doi:10.1158/0008-5472.CAN-06-101016912155
   PubMed Web of Science ®Google Scholar
• Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone H-J, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res. 2000;60(23):6714–6722.11118057
   PubMed Web of Science ®Google Scholar
• Li Z. CD133: a stem cell biomarker and beyond. Exp Hematol Oncol. 2013;2(1):17. doi:10.1186/2162-3619-2-1723815814
   PubMedGoogle Scholar
• Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27(12):1749–1758. doi:10.1038/sj.onc.121081117891174
   PubMed Web of Science ®Google Scholar
• Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC. Theodorescu D.CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res. 2011;71(11):3802–3811. doi:10.1158/0008-5472.CAN-11-051921482678
   PubMed Web of Science ®Google Scholar
• Kohga K, Tatsumi T, Takehara T, et al. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol. 2010;52(6):872–879. doi:10.1016/j.jhep.2009.12.03020395004
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu Y, Feng H, et al. CD133 affects the invasive ability of HCT116 cells by regulating TIMP-2. Am J Pathol. 2013;182(2):565–576. doi:10.1016/j.ajpath.2012.10.01523195431
   PubMed Web of Science ®Google Scholar
• Long H, Xie R, Xiang T, et al. Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells. 2012;30(10):2309–2319. doi:10.1002/stem.119422887854
   PubMed Web of Science ®Google Scholar
• Zhang SS, Han ZP, Jing YY, et al. CD133+CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med. 2012;10:85. doi:10.1186/1741-7015-10-8522871210
   PubMed Web of Science ®Google Scholar
• Lerner SP, McConkey DJ, Hoadley KA, et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer. 2016;2(1):37–47. doi:10.3233/BLC-15003727376123
   PubMedGoogle Scholar
• McConkey DJ, Choi W. Molecular subtypes of bladder cancer. Curr Oncol Rep. 2018;20(10):77. doi:10.1007/s11912-018-0727-530128829
   PubMed Web of Science ®Google Scholar
• Polyak K. Heterogeneity in breast cancer. J Clin Invest. 2011;121(10):3786–3788. doi:10.1172/JCI6053421965334
   PubMed Web of Science ®Google Scholar
• Prieto-Vila M, Takahashi RU, Usuba W, et al. Drug resistance driven by cancer stem cells and their niche (review). Int J Mol Sci. 2017;18(12) pii:E2574. doi:10.3390/ijms1812257429194401
   PubMed Web of Science ®Google Scholar